JUNE 2017

Leader in Canadian Medical Cannabisand International First Mover

DISCLAIMER

GENERAL

This documentation is a presentation of general background information about the activities of CanniMed Therapeutics Inc. (the “Company”, “CMED”, “us” or “we”). The information contained in this presentation is derivedsolely from otherwise publicly available information concerning CMED and does not purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make aninvestment in CMED.

This presentation does not constitute or form part of any offer or invitation for the sale or purchase of securities or any of the assets, business or undertaking described herein nor shall it or any part of it form the basis ofor be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this presentation who are considering acquiring securities of CMED are reminded thatany such purchase or subscription must not be made on the basis of the information contained in this presentation but are referred to the continuous disclosure documents of CMED filed on SEDAR at www.sedar.com.The contents of this presentation are not to be construed as legal, financial or tax advice. Each prospective investor should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal,financial or tax advice.

No representation or warranty, express or implied, is made or given by or on behalf of CMED or any of its affiliates or subsidiary undertakings or any of the directors, officers or employees of any such entities as to theaccuracy, completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any person for such information or opinions. In furnishing this presentation,CMED does not undertake or agree to any obligation to provide the attendees with access to any additional information or to update this presentation or to correct any inaccuracies in, or omissions from, this presentationthat may become apparent. No person has been authorised to give any information or make any representations other than those contained in this presentation and, if given and/or made, such information orrepresentations must not be relied upon as having been so authorised. The information and opinions contained in this presentation are provided as at the date of this presentation.

In this presentation, all amounts are in Canadian dollars, unless otherwise indicated. Any graphs, tables or other information in this presentation demonstrating the historical performance of CMED or any other entitycontained in this presentation are intended only to illustrate past performance of such entities and are not necessarily indicative of future performance of CMED or such entities.

This presentation is being supplied to you solely for your information and may not be reproduced, further distributed or published in whole or in part by any other person. Distribution of this presentation may be restrictedor prohibited by law. Recipients are required to inform themselves of, and comply with, all such restrictions or prohibitions and CMED does not accept liability to any person in relation thereto.

FORWARD-LOOKING INFORMATION

This presentation contains “forward-looking information” within the meaning of applicable securities laws in Canada. Forward-looking information may relate to our future outlook and anticipated events or results andmay include information regarding our financial position, business strategy, growth strategies, budgets, operations, financial results, taxes, dividend policy, plans and objectives. Particularly, information regarding ourexpectations of future results, performance, achievements, prospects or opportunities or the markets in which we operates is forward-looking information. In some cases, forward-looking information can be identified bythe use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “an opportunity exists”, “outlook”, “prospects”, “strategy”, “intends”, “believes”, or variations of such words and phrases orstate that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, intentions, projections or othercharacterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations,estimates and projections regarding future events or circumstances.

Forward-looking information contained in this presentation and other forward-looking information are based on our opinions, estimates and assumptions in light of our experience and perception of historical trends,current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct.

Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information in this presentation, there may be other risk factorsnot presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in thispresentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers shouldnot place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this presentation represents our expectations as of the date of thispresentation or the date indicated, regardless of the time of delivery of the presentation. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as aresult of new information, future events or otherwise, except as required under applicable securities laws in Canada. All of the forward-looking information contained in this presentation is expressly qualified by theforegoing cautionary statements.

NON-IFRS MEASURES AND INDUSTRY METRICS

This presentation makes reference to certain non-IFRS measures including “EBITDA” and “Adjusted EBITDA”, and to certain operating metrics in the industry. Non-IFRS measures including industry metrics do not have astandardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complementthose IFRS measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis ofour financial information reported under IFRS. Please refer to the Prospectus for further details on these non-IFRS measures including industry metrics, including relevant definitions and reconciliations.

2

SUMMARY OVERVIEW

CanniMed Therapeutics Inc.

3

An international, biopharmaceutical company anda leader in the Canadian cannabis industry withbest-in-class pharmaceutical-grade cannabisproducts and a first mover advantage in rapidlyemerging international markets

Experienced LP with a 15 year history of growing medical cannabisINVESTOR HIGHLIGHTS

Pharmaceutical-Grade; GMP-compliant;investing inclinical trials

The Canadianmedical market is

First mover

Strong managementand boardwith broad experience incannabis, medical biotechnology,and pharmaceuticals

4

SignificantRevenue, EBITDAand VolumeGrowth

to address the massive

advantage andbest positioned

internationalmarket opportunity

here and nowwith growing acceptance;increasing evidence ofeffectiveness; Baby Boomers area significant market opportunity

RecentDevelopments

Strong 1H 2017results

KG SOLD

(+77.2% H/H)

ADJUSTED EBITDA

(+$1.2MM H/H)

REVENUE

(+78.1% H/H)

Entered into Canada’s First ExclusivePharmacy Distribution Agreement forMedical Cannabis

Commenced $10.5MM Cannabis OilsFacility Expansion with Support of theSaskatchewan Provincial Government

Agreement with CTT PharmaceuticalHoldings Inc. (“CTT”) to License its OrallyDissolvable Thin Film Wafer

5

Completed oils exports to Australia andCayman Islands and received follow-uporder for 360,000 ml of CanniMed® oilsto Australia

Pharmaceutical Cannabis

6

THE OPPORTUNITY IS SIGNIFICANT

Increased riskof addiction,overdose andmortality

A strong needfor alternativemethods for painmanagement

Seeking pain reliefand maintaining anactive lifestyle andmanage end-of-lifeconditions

Legislative, politicalenvironments aremore favorabletowards medicalcannabis globally

Commonlyprescribed opioids

Increasinghealthcare costs

Rapidly agingpopulation

Canadais a leader

Here and Now

7

THE CANADIAN MEDICAL MARKET

2015 Q1 16 Q2 16 Q3 16

6,704

584

8,807

11,473

14,373

2,084

4,504

Herbal (kg)

Q/Q growth inRegistered Patients

32%

8% Q/Q growthin Herbal

70% Q/Q growth in Oil

Cannabis oils have greatly accelerated market growth

7

Cannabis Oil (kg)

(1) Rolling 12 months. Shown as at the end of the reporting period. Includes wholesale sales.

Q4 16

14,373

17,026

8,613

BABY BOOMERS

To Provide a Step-Change in Demand

8(1) Pain Resource Centre, 2015: Pain in Canada Fact Sheet (2) Canadian Pain Society. (3) Direct costs. Pain Resource Centre, 2015: Pain in Canada Fact Sheet. (4) The CanadianPain Society, 2011: Call to Action: The Need for a National Pain Strategy for Canada. (5) Globe and Mail, October 2014. (6) Canadian Centre on Substance Abuse, July 2015.

$2

$193

2015

2010

21.72015

2010

1 in 5Canadianadults sufferfrom chronicpain(2)

Chronicpain costsmore than$6 billionannually(3)

Inadequate painassessment andtreatment is agrowing problemin Canada(4)

Opioids areprescribed forchronic paindespite littleevidence of longterm efficacy(5)

With an agingpopulation, theincidence ofchronic painincreases(1)

29%of the Canadianpopulation

16% of seniors use opioids(6)

New delivery mechanisms suchas cannabis oils and gelcaps areideally suited:

• More traditional forms

• Easier to target symptoms/doses

• Avoid stigmas associatedwith smoking

INTERNATIONAL MARKETS

Opportunities are Exploding

9

International markets are opening very quicklyfor pharma-quality products

9

Cayman Islands

Fulfilled order of12,960ml of Oils tothe Cayman Islands

United States

Ownership of GMPcompliant production facilitywith potential to supportover 50,000kg of capacityper annum

In process of applyingto the DEA for a licence

DEA to allow for increasedsupply for research purposes

Australia

Completed the first evershipment of commercialcannabis oil and receivedthree subsequent orders for360,000ml of Oil products

Worldwide population of babyboomers is over 1.1 billion ~121.4 Million

Europe

baby boomers~73.8 MillionU.S

baby boomers~5.0 MillionAustralia

baby boomers

European Union

Entered into a LOI with Creso Pharma Ltd.for the purpose of marketing CMEDMedical Cannabis Brands

GMP Compliant

Extensive qualitycontrol

Precision growingand extraction

No pesticides

CanniMed is focused onproducing high-qualityproducts that are bestpositioned in any market

Well Positioned forthe near and long term

10

CANNIMED THERAPEUTICS

(1) GMP are standards and procedures that pharmaceuticalcompanies must adhere to in manufacturing their products in NorthAmerica; part of quality assurance that ensures that drugs areconsistently produced and controlled to meet quality standards

FRAMEWORK STILL TBD

Recreational

Medical

Product

will be keydifferentiation

CMEDProvide significant opportunity

best-in-class oils

– particularly in consumables

High margin

New delivery mechanismsprovide opportunities for IP

distributionPharmacywill be a game changer

to international marketsOnly pathway

OPPORTUNITY IS NOW

HerbalCANNIMED PRODUCT OFFERING

Pharmaceutical-quality and brandingpromotes doctor confidence and supportsmore effective prescription dosages

Identified by thepercentage of THCand CBD theycontain

Each product is designed withspecific benefits in mind toaddress each patient’srequirements

Purple 1·13

0.7% THC

13.0% CBD

Red 4·10

4.0% THC

10.0% CBD

Orange 9·9

9.0% THC

9.5% CBD

Yellow 12·0

12.5% THC

<0.5% CBD

Green 15·5

15.0% THC

5.0% CBD

Blue 17·1

17.0% THC

0.7% CBD

Indigo 22·1

22.0% THC

0.7% CBD

11

OilsCANNIMED PRODUCT OFFERING

For patients reluctant to smoke herbal product

• Ideal for palliative care and hospitalized patients

• Significant sales acceleration since launching oils in Q1 2016

For baby boomers looking for a safe,reliable way to manage their chronic painsymptoms and maintain an active lifestyle

PRODUCTION Ramp 2H 2017CANNABIS OILS

Higher margin, value-added products with

Purple 1·20

0.720.060

THC mg/mlCBD mg/mlTHC mgTOTAL CBD mg1,200

Orange 10·10

9.89.9588

TOTAL CBD mg594

THC mg/mlCBD mg/mlTHC mg

Blue 18·0

18.30.21,09812

THC mg/mlCBD mg/mlTHC mgTOTAL CBD mg

12

global market appeal

GEL CAPS

adding 5,000 kg additional capacity in 2018

Saskatoon, Saskatchewan

13

GMP-COMPLIANT PRODUCTION FACILITIES

(1) Benefited from the technologies and innovations advanced over the course of seven distinct facility builds.

Good ProductionPractices (GPP)Required under ACMPR

InternationalOrganization forStandardization (ISO)

GMP StandardsOnly LP deemed by HealthCanada to be compliant

Required for pharmaceuticalproduction

GMP

97,000 sq. ft.above-ground production facility

30 large individual biosecure growth chambers

7,000 kg current capacity;

State-of-the-art, GMP-compliant

5 separate Level 7 “SeventhGeneration”facility(1)

production process

MOST RIGOROUS

RIGOROUS

LEAST RIGOROUS

security compliantvaults

Above ground facility on 100 acres,currently using approximately 20 acres

Clinical Trials

1414

• “CAPRI Trial”(1)

- First Phase II Health Canada approved clinicaltrial using cannabis ($1 million invested)- Randomized, double-blind, placebocontrolled, proof-of-concept Phase IIA clinicaltrial- Seeks to examine the varying ratios of THC andCBD in patients with osteoarthritis of the knee

• “Identifying the molecular mechanisms involvedin suppressing multiple sclerosis inducedneuropathic pain following cannabinoidtreatment in an animal model of multiplesclerosis” the Company’s pre-clinical studypartnered with Dr. Namaka at the University ofManitoba.

• “CARE-E Trial” in patients with refractory pediatricepilepsy, partnered with Dr. Richard Huntsman atthe University of Saskatchewan.

• “PICATE Trial” in patients with Tourette’ssyndrome, partnered with Dr. Paul Sandor atToronto Western Hospital.

(1) Cannabinoid Profile Investigation of Vaporized Cannabis in Patients with Osteoarthritis of the Knee

Investing in Medical Care

Growing MomentumREVENUE AND GROWTH

(1) Includes both dried herbal and oils1515

Total Dried Equivalents(KG)(1)

Oil Equivalent(KG)

341.3

403229

714

49

% of Revenue18.9% 45.1%

1H 2016 1H 2017H1 2016

Patients Physicians

25,991

10,224

2,385

H1 2017

3,840

s

Historical Financials

16

REVENUE AND GROWTH

(1) Financial results as of Q1 ending January 31, 2017; (2) Includes MMPR

Achieved

Aggressively expandinginfrastructure to meetaccelerating market demand

Total Revenue(1)(2) Oil Revenue (1)(2)

ExperiencingRapid Sales

Growth

32%of kg Soldin 1H 2017

Cannabis Oils

of $0.2MM in 1H 2017positive adj. EBITDA Launching oils in Q1 2016 has accelerated

growth and expanded opportunities fornew customers

Introduction of pharmaceutical-grade

in Canada and internationallygel caps anticipated to accelerate growth

201598.2% Margin

201683.7% Margin

LTM80.7% Margin

1H 2016 1H 2017

$5.8 $5.7

$9.8$8.2

$12.9

$8.9

$4.0 $3.5

$7.1

$4.1

CapitalizationREVENUE AND GROWTH

17 (1) As of close of June 12, 2017; shares outstanding as of Q2 Year-End: 22,670,933

OCTOBER 31, 2016FISCAL YEAR-END ($M)

April 30, 2017Q2 ($M)

CASH 2.0 59.0

TOTAL CURRENT ASSETS 14.7 72.1

CURRENT LIABILITIES 7.8 6.1

DEBT 29.6 17.7

SHAREHOLDERS EQUITY 10.6 91.8

CURRENT MARKET CAPITALIZATION(June 12, 2017)

$196.8(1)

CURRENT ENTERPRISE VALUE $155.5(1)

Strong Management Team and Board

18

KEY MANAGEMENT

President & CEO

Brent H. Zettl

• President of CanniMed since 1991

• Spearheaded the development activities of theinnovative underground growth chambers

• 2014 E&Y Entrepreneur of the Year for thePrairies Business-to-Consumer category

CFO

John Knowles

• Over 30 years experience in senior executive andboard roles in Canada and internationally

• A Director of CanniMed for over eight years and pastChair of the Audit and Finance Board Committee

• Former VP, CFO of Hudbay Minerals Inc., Executive VPof Aur Resources Inc., and CEO of LiCo Energy MetalsInc.

Chief Research Officer

Larry Holbrook

• Background includes Senior Research Scientistpositions with extensive and diverse agriculturalbiotechnology experience in both governmentand industrial settings

• Over 20 years of experience in basic research andapplications to genetic modification of crop plants

• Author or co-author on 40 publications and books

VP, Business Development and Regulatory Affairs

Gulwant Bajwa

• Previously with Health Canada as a Senior ProgramManager in former Bureau of Medical Cannabisand as a Policy Analyst in the Intellectual Propertyand Technology Transfer office of Health Canada

• Five years as Director of Operations at JDSUniphase Corporation

Strong Management Team and Board

19

BOARD OF DIRECTORS

LL.B, B.A. (Chairman)

Donald Ching

Director, Golden Opportunities Fund;Former President and CEO of SaskTel

Doug Banzet

CFO and Director, GoldenOpportunities Fund

B.B.A.

Rob Duguid

Partner, PFM Capital; VP, PrairieVentures Fund

Ph.D.

Marianne Greer

Independent Pharmacist Consultant

B.Sc.

Richard Hoyt

VP, Business Development,Mallinckrodt PLC

B.Comm, C.P.A., C.A.

Dwayne L. Lashyn

VP, Quantico Capital Corp.

Ph.D., J.D.

Bruce F. Mackler

Consultant in FDA, USDA and EPARegulatory Processes

Ph.D.

Brandon J. Price

Executive VP, Nascent Biotech;Co-founder, Biogenin

B.Comm, C.P.A., C.A.John L. Knowles

CFO and Director,CanniMed Therapeutics Inc.

Brent Zettl

President, CEO and Director,CanniMed Therapeutics Inc.

B.S.AB.B.A.